These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 25719692

  • 1. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines.
    Kim JE, Song EJ, Choi GS, Lew BL, Sim WY, Kang H.
    Plast Reconstr Surg; 2015 Mar; 135(3):732-741. PubMed ID: 25719692
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y, Fang F, Lai W, Li C, Li L, Liu Q, Lu J, Pang X, Sun J, Shi X, Picaut P, Prygova I, Andriopoulos B, Sun Q.
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [Abstract] [Full Text] [Related]

  • 3. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.
    Carruthers A, Carruthers J.
    Dermatol Surg; 2005 Oct; 31(10):1297-303. PubMed ID: 16188182
    [Abstract] [Full Text] [Related]

  • 4. Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.
    Frampton JE, Easthope SE.
    Am J Clin Dermatol; 2003 Oct; 4(10):709-25. PubMed ID: 14507232
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
    Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, Walker P, Eadie N, BOTOX Glabellar Lines I Study Group.
    J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
    [Abstract] [Full Text] [Related]

  • 7. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W, Rappl T.
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
    Won CH, Lee HM, Lee WS, Kang H, Kim BJ, Kim WS, Lee JH, Lee DH, Huh CH.
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A, Carruthers J, Coleman WP, Donofrio L, Flynn T, Gold M, Heinz M, Harrington L, Jones D, McDaniel D, Rohrer T, Schlöbe A, Solish N, Weiss RA.
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Botulinum Toxin Type A for Treatment of Glabellar Lines: A Network Meta-Analysis of Randomized Controlled Trials.
    Li X, Sui C, Xia X, Chen X.
    Aesthetic Plast Surg; 2023 Feb; 47(1):365-377. PubMed ID: 36097079
    [Abstract] [Full Text] [Related]

  • 16. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW, Narins RS, Brandt F, Cohen JL, Donofrio LM, Downie J, Heinz M, Harrington L, McDaniel DH, Nestor M, Schlessinger J, Schlöbe A, Taub A, Weiss RA.
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the safety and efficacy of botulinum toxin type A and topical creams for treating moderate-to-severe glabellar rhytids.
    Beer KR.
    Dermatol Surg; 2006 Feb; 32(2):184-97. PubMed ID: 16442037
    [Abstract] [Full Text] [Related]

  • 18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients.
    Rzany BJ, Ascher B, Avelar RL, Bergdahl J, Bertucci V, Bodokh I, Carruthers JA, Cartier H, Delmar H, Denfeld R, Gross JE, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Sattler G, Sebastian M, Solish N, Swift A, Trévidic P.
    Aesthet Surg J; 2020 Mar 23; 40(4):413-429. PubMed ID: 30951166
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies.
    Beer KR, Shamban AT, Avelar RL, Gross JE, Jonker A.
    Dermatol Surg; 2019 Nov 23; 45(11):1381-1393. PubMed ID: 30893162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.